WO2006082649A1 - 多嚢胞性卵巣症候群(pcos)治療剤 - Google Patents
多嚢胞性卵巣症候群(pcos)治療剤 Download PDFInfo
- Publication number
- WO2006082649A1 WO2006082649A1 PCT/JP2005/001697 JP2005001697W WO2006082649A1 WO 2006082649 A1 WO2006082649 A1 WO 2006082649A1 JP 2005001697 W JP2005001697 W JP 2005001697W WO 2006082649 A1 WO2006082649 A1 WO 2006082649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pcos
- maitake
- extract
- polycystic ovary
- ovary syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Definitions
- PCOS polycystic ovary syndrome
- the present invention relates to an effective and safe therapeutic agent for polycystic ovary syndrome (PCOS), which causes infertility, menstrual abnormalities, acne, hirsutism, and obesity in women.
- PCOS polycystic ovary syndrome
- PCOS polycystic ovary syndrome
- gonadal-stimulating hormones gonadal-stimulating hormones
- FSH Follicle-stimulating hormone
- LH I body
- PCOS Polycystic ovary syndrome
- Clomifen works on the hypothalamus to cause ovulation, but ovulation may not occur.
- HMG human menopausal gonadotropins
- Gonadotropin (gonadotropin) is injected into a patient and stimulates the ovary to induce ovulation. This treatment is relatively effective and has a good pregnancy rate, but multiple pregnancies are likely to cause side effects such as Ovarian hyperstimulation syndrome (OHSS) and V! /. .
- a laparoscope to irradiate the surface of the ovary with a laser beam to open a small hole.
- PCOS polycystic ovary syndrome
- PCOS polycystic ovary syndrome
- the treatment is mainly aimed at ovulation as described above.
- treatments with ovulation inducers such as (I)-(III) are considered trumps for infertility treatment, but they cause serious side effects such as multiple pregnancy and ovarian hyperstimulation syndrome (OHSS).
- OHSS hyperstimulation syndrome
- PCOS polycystic ovary syndrome
- the present invention has been made in view of the above problems, and is effective even for unmarried or young women who are effective with almost no side effects, improve anovulation, and who use the power of women who want to have a baby.
- the object is to provide a therapeutic agent for polycystic ovary syndrome (PCOS) that can be used safely.
- PCOS polycystic ovary syndrome
- the present invention is a therapeutic agent for polycystic ovary syndrome (P cos) comprising an extract of mushrooms as an active ingredient.
- the mushrooms are most preferably maitake, more preferably one or more selected from the group consisting of maitake, shitake, agaritas, litchi, and oyster mushrooms.
- the mushroom extract includes (1) mushroom raw material (mushroom fruit body and Z or mycelium collectively "mushroom raw material” t, etc.) ethanol having a concentration of 90% or more. (2) After that, hot water extraction is performed, and ethanol is added to the obtained hot water extract until the final volume concentration is 50-75%. It is preferably produced by a process comprising the steps of removing components and obtaining a supernatant, and (3) collecting a fraction having a molecular weight of 14,000 or more from the obtained supernatant. ,.
- the invention's effect is preferably produced by a process comprising the steps of removing components and obtaining a supernatant, and (3) collecting a fraction having a molecular weight of 14,000 or more from the obtained supernatant. ,.
- the therapeutic agent for polycystic ovary syndrome (PCOS) according to the present invention has an excellent effect of improving anovulation which is safe and has few side effects by using an extract of mushrooms as an active ingredient. It can also be used safely for unmarried and young women who want to raise their children.
- FIG. 1 is a chart showing the results of high performance liquid chromatography (HPL C) analysis of the maitake extract obtained in Production Example 1. (Analysis example)
- FIG. 2 is a chart showing the results of high-performance liquid chromatography (HPL C) analysis of shiitake extract obtained in Production Example 3. (Production Example 3)
- FIG. 3 is a chart showing the results of high performance liquid chromatography (HP LC) analysis of the agaritas extract obtained in Production Example 4. (Production Example 4)
- FIG. 4 is a chart showing the results of high-performance liquid chromatography (HPLC) analysis of the litchi extract obtained in Production Example 5. (Production Example 5)
- FIG. 5 is a chart showing the results of high performance liquid chromatography (HPL C) analysis of the oyster mushroom extract obtained in Production Example 6. (Production Example 6)
- the therapeutic agent for polycystic ovary syndrome (PCOS) of the present invention comprises an extract of mushrooms as an active ingredient It is what.
- This mushroom extract can be used as a treatment method for polycystic ovary syndrome (PCOS).
- This mushroom extract can also be used to produce a therapeutic agent for polycystic ovary syndrome (PCOS).
- the maitake is more preferably at least one selected from the group consisting of maitake, shiitake, agaritas, litchi, and oyster mushrooms.
- These mushrooms include glycoproteins, which are saccharide-bound proteins (complex proteins), and these mushroom mosquito extracts according to the present invention are mainly composed of this glycoprotein. It is considered to be included.
- Glycoprotein which is the main component of the mushroom extract according to the present invention, is brown, exhibits water solubility and thermal stability, and has a mass ratio of simple protein portion to carbohydrate portion of 75: 2 5 ⁇ 90: 10, molecular weight distribution is 18,000 ⁇ 22,000, and positive for burette reaction and feeling reaction.
- the “simple protein portion” refers to a portion of a glycoprotein that is a complex protein that only the polypeptide chain is capable of.
- the molecular weight distribution of the glycoprotein is preferably 18,000 to 22,000, and the average molecular weight is more preferably 20,000.
- Thermal stability means that biological activity is not lost even after standing for 15 to 15 hours at 80-130 ° C.
- the mushroom extract according to the present invention includes (1) the above-mentioned mushroom raw material (mushroom fruit body). And / or mycelium) is treated with ethanol at a concentration of 90% or more to remove ethanol-soluble components. (2) Thereafter, hot water extraction is performed, and the final volume concentration of the obtained hot water extract is reduced. 50-75% ethanol is added to remove the insoluble components that are produced, and a supernatant is obtained. (3) From the obtained supernatant, a fraction having a molecular weight of 14,000 or more is collected. It is preferable to be manufactured by a process including a process.
- the method for producing an extract of mushrooms according to the present invention includes the above-mentioned steps (1)-(3).
- (1) mushroom materials used in the present invention are treated with ethanol having a concentration of 90% or more to remove ethanol-soluble components.
- a fresh product of the above mushroom raw material or a dried product thereof can be used without particular limitation.
- a dry powder from the viewpoint of efficient treatment.
- the ethanol having a concentration of 90% or more may be water containing 90% or more of ethanol (ethanol water).
- ethanol water from the viewpoint of efficiently removing ethanol-soluble components from which mushroom raw materials have been dissolved, water containing 95% or more of ethanol is preferred, and ethanol is most preferably 100%.
- the treatment in the step (1) means that mushroom raw materials are mixed with ethanol or ethanol water and stirred.
- the content of the mushroom raw material at this time is preferably 10-25% by mass, more preferably 10-12. 5% by mass.
- the processing temperature is 20-70 ° C, but it may be room temperature.
- the treatment time depends on the state of the mushroom raw material to be used and the treatment temperature, but it is preferably 1 to 10 hours and more preferably 2 to 3 hours.
- mushroom raw material strength ethanol-soluble component strength Dissolves in ethanol or ethanol water. Dissolved ethanol-soluble components are unnecessary and should be removed by filtration or centrifugation. Among them, it is preferable to use centrifugation from the viewpoint of mass processing.
- step (2) hot water extraction is performed from the ethanol extraction residue from which ethanol-soluble components have been removed, and the resulting hot water extract is ethanol until the final volume concentration is 50-75%. Is added to remove the insoluble components formed, and a supernatant is obtained.
- the hot water extraction is to add water to the ethanol extraction residue obtained in the step (1) and heat it.
- the ethanol extraction residue concentration at this time is preferably 10-25% by mass 1 It is more preferably 0 to 12.5% by mass.
- the heating temperature is preferably 80-130 ° C, more preferably 100-120 ° C.
- the extraction time is preferably 1 to 15 hours, more preferably 2 to 3 hours.
- the components insoluble in this solution are filtered off, and ethanol is added to the hot water extract, which is the filtrate after filtration, until the final volume concentration is 50-75%. It may be efficient to concentrate the hot water extract to a volume of 1Z3-1Z2 before adding ethanol.
- the ethanol After the ethanol is prepared, it is allowed to stand at low temperature, preferably 0 ° C to room temperature, more preferably 4 to 10 ° C for 5 to 24 hours, preferably 8 to 12 hours. It is preferable to promote the formation of some precipitates and suspended solids. Thereafter, the generated insoluble components are removed by centrifugation or filtration, and a supernatant containing a filtrate or the like is obtained. By removing insoluble components produced by the addition of ethanol, substances having immunosuppressive action and the like can be substantially removed from the final product.
- a fraction having a molecular weight of 14,000 or more is collected from the obtained supernatant.
- the collection of fractions with a molecular weight of 14,000 or more is preferably carried out using dialysis or ultrafiltration.
- dialysis membrane used for this dialysis or ultrafiltration a general membrane such as cellophane membrane or collodion membrane can be used as long as it has a molecular weight cut off of 1,400.
- the obtained fraction having a molecular weight of 14,000 or more may be purified for the purpose of further increasing the purity.
- a purification method for example, a method often used for purification of glycoprotein, such as gel filtration chromatography, can be used without particular limitation.
- the solvent used in the production of the above mushroom extract is approved by the Japanese Ministry of Health, Labor and Welfare for use in the production of health food materials, and this extract is also used as a health food material. Can be used.
- the therapeutic agent for polycystic ovary syndrome (PCOS) of the present invention can contain a pharmaceutically acceptable carrier and Z or a diluent in addition to the above-mentioned extract of mushrooms as an active ingredient.
- a pharmaceutically acceptable carrier for example, cellulose, calcium monohydrogen phosphate, sucrose fatty acid ester, silicon dioxide, methyl cellulose, ratatose and the like can be used.
- a diluent water, glycerol, etc. can be used, for example. Add some common additives such as preservatives, stabilizers, excipients, binders, disintegrants, and sweeteners.
- the therapeutic agent for polycystic ovary syndrome (PCOS) of the present invention can be administered orally, parenterally or transdermally.
- the amount of the active ingredient to be administered is desirably determined appropriately according to the weight of the patient, the nature of the disease, the condition, the administration route, and the like. Among them, 50 to 800 mgZ per oral dose is preferable, preferably 100 to 500 mgZ, most preferably 200 to 350 mgZ, and this is once a day. Dosage in several doses.
- the mushroom extract according to the present invention can be used by itself or together with other pharmacologically active substances. Suitable forms for administration include, for example, plain tablets or coated tablets, capsules, suppositories, solutions, syrups, emulsions or dispersible powders.
- the tablet or the like preferably contains 3 to 80% by mass, more preferably 5 to 50% by mass, of the mushroom extract according to the present invention.
- Tablets include, for example, one or more active substances, known excipients, for example, inactive ingredients such as calcium carbonate, calcium phosphate, and ratatose; disintegrants such as constarch and alginic acid; binding of starch, gelatin, and the like Agents; lubricants such as magnesium stearate and talc; and agents that give delayed release such as Z or carboxymethylcellulose, cellulose acetate phthalate, polybutylacetate, and extracts of the mushrooms according to the present invention, or And other pharmacologically active substances.
- a tablet consists of several layers.
- Coated tablets can be produced by coating a core produced in the same manner as tablets with a substance usually used for tablet coating, such as gum arabic, talc, titanium dioxide, methylcellulose, sucrose, and the like.
- a substance usually used for tablet coating such as gum arabic, talc, titanium dioxide, methylcellulose, sucrose, and the like.
- the core to obtain delayed release and to avoid incompatibility may consist of several layers.
- tablet coatings may have some laminar strength to provide delayed release and the above excipients for tablets can be used.
- the syrup containing the extract of the mushrooms according to the present invention or a combination thereof with other pharmacologically active substances is a sweetener such as saccharin, cyclamate, glycerol, sucrose, and flavor. Contains flavoring agents such as vanillin and orange extract. It may be. It may also contain a suspending aid or thickener such as sodium carboxymethylcellulose; a wetting agent such as a condensate of an aliphatic alcohol and ethylene oxide; or a preservative such as P-hydroxybenzoate. .
- the capsule containing the extract of the mushrooms according to the present invention or a combination thereof with other pharmacologically active substances includes, for example, these substances and an inert carrier such as latatose and sorbitol. And the mixture is sealed in a gelatin capsule or the like.
- the suppository is, for example, an extract of the mushrooms according to the present invention, or a combination of this and another pharmacologically active substance, which is a conventional carrier, specifically, neutral fat, polyethylene glycol. Or it can manufacture by mixing with the derivative (s) etc.
- the mushroom extract according to the present invention may be a food such as health food, functional food or general food. Since the glycoprotein in the present invention is an extract of mushrooms, it is excellent in safety, and the food can be ingested constantly. These foods may contain vitamins, minerals, herbs, and other nutritional materials in addition to the above-mentioned calorie ingredients.
- a fraction having a molecular weight of 14,000 or more was collected by dialysis to obtain a maitake extract.
- this maitake extract In order to analyze this maitake extract, it was purified by gel filtration chromatography to obtain about 21 g of a brown substance. When this purified maitake extract was subjected to a burette reaction and a felting reaction, it was positive. Thus, it was confirmed to contain a protein portion and a carbohydrate portion.
- the simple protein portion was quantified by the Bradford method.
- the analysis of amino acids constituting the simple protein portion was performed using an automatic amino acid analyzer (Hitachi L-8500A Amino Acid Analyzer).
- the saccharide portion was quantified by the phenol sulfate method, and the saccharide portion composition was determined by high performance liquid chromatography (HPLC). Molecular weight was measured by SDS-PAGE electrophoresis. -NMR measurements were also performed.
- Table 1 shows the analysis results of the mass ratio of the simple protein portion and the carbohydrate portion in the purified maitake extract. The substance proved to be a glycoprotein.
- Fig. 1 shows a chart of high-performance liquid chromatography (HPLC) analysis results of the maitake extract obtained in Production Example 1.
- HPLC high-performance liquid chromatography
- glycoprotein as the main component in the obtained maitake extract had the following properties.
- Solubility soluble in water and alkaline solutions
- Amino acid composition of simple protein part Asparagine, glutamine, serine, threonine, glycine, alanine, norin, cystine, methionine, isoleucine, leucine, thymusin, phenylalanine, lysine, histidine, arginine, proline
- Carbohydrate composition galactose, mannose, glucose, N-acetyl chloride, fucose
- the powder of dried maitake is a powder obtained by simply drying and pulverizing maitake and is not subjected to ethanol extraction.
- the above-mentioned maitake extract (powder) and dried maitake powder are mixed with finely crushed auxiliaries, granulated, dried, crushed, compressed into tablets of appropriate shape and size. After that, a coating material was applied.
- [0063] Manufacture and analysis of extracts from shitake mushrooms, agaritas, litchi, and oyster mushrooms.
- a mushroom extract was produced in the same manner as in Production Example 1 except that Production Example 5) and Oyster Mushroom (Production Example 6) were used. These extracts were subjected to HPLC measurement in the same manner as in the above analysis example.
- Fig. 2 shows a chart of the HPLC analysis results for shiitake extract
- Fig. 3 shows a chart of the HPLC analysis results of the agaricus extract
- Fig. 4 shows a chart of the HPLC analysis results of the litchi extract.
- Figure 5 shows charts of HPLC analysis results for oyster mushroom extracts.
- Fig. 2 shows a chart of the HPLC analysis results for shiitake extract
- Fig. 3 shows a chart of the HPLC analysis results of the agaricus extract
- Fig. 4 shows a chart of the HPLC analysis results of the litchi extract.
- Figure 5 shows charts of HPLC analysis results for
- PCOS polycystic ovary syndrome
- Table 2 shows the results of comparison of the ovulation rate according to the number of ovulated patients.
- Table 3 shows the results of comparison based on the number of cycles ovulated.
- a safety test was conducted using 10 male and 4 female ICR mice of 4 weeks old. After measuring the body weight of these mice 4 hours after fasting, the test group was prepared by dissolving the maitake extract obtained in Production Example 1 in distilled water with a dose of 2, OOOmgZkg body weight. Forced single administration using a stomach tube. In the control group, 0.7 mL of pure water and 0.6 mL of female were administered in the same manner. The observation period was 14 days, and all were necropsied after the observation period.
- the L D value after single oral administration to the mouse of the mushroom extract according to the present invention is considered to be 2,000 mg / kg body weight or more in both males and females.
- the coconut extract was confirmed to be highly safe. Industrial applicability
- the therapeutic agent for polycystic ovary syndrome (PCOS) of the present invention has an excellent effect of improving anovulation which is safe and has few side effects by using an extract of mushrooms as an active ingredient. It can also be safely applied to unmarried and young women who want the power of their choice.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006517881A JP4464964B2 (ja) | 2005-02-04 | 2005-02-04 | 多嚢胞性卵巣症候群(pcos)治療剤 |
PCT/JP2005/001697 WO2006082649A1 (ja) | 2005-02-04 | 2005-02-04 | 多嚢胞性卵巣症候群(pcos)治療剤 |
CA2590549A CA2590549C (en) | 2005-02-04 | 2005-02-04 | Therapeutic agent for polycystic ovary syndrome (pcos) |
US11/573,726 US20070298049A1 (en) | 2003-08-27 | 2005-02-04 | Therapeutic Agent for Polycystic Ovary Syndrome (Pcos) |
US12/535,308 US8168198B2 (en) | 2003-08-27 | 2009-08-04 | Therapeutic agent for polycystic ovary syndrome (PCOS) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2005/001697 WO2006082649A1 (ja) | 2005-02-04 | 2005-02-04 | 多嚢胞性卵巣症候群(pcos)治療剤 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/573,726 A-371-Of-International US20070298049A1 (en) | 2003-08-27 | 2005-02-04 | Therapeutic Agent for Polycystic Ovary Syndrome (Pcos) |
US12/535,308 Continuation US8168198B2 (en) | 2003-08-27 | 2009-08-04 | Therapeutic agent for polycystic ovary syndrome (PCOS) |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006082649A1 true WO2006082649A1 (ja) | 2006-08-10 |
Family
ID=36777044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001697 WO2006082649A1 (ja) | 2003-08-27 | 2005-02-04 | 多嚢胞性卵巣症候群(pcos)治療剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4464964B2 (ja) |
CA (1) | CA2590549C (ja) |
WO (1) | WO2006082649A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168198B2 (en) | 2003-08-27 | 2012-05-01 | Kunihiko Tominaga | Therapeutic agent for polycystic ovary syndrome (PCOS) |
CN104689070A (zh) * | 2015-02-26 | 2015-06-10 | 魏代淑 | 一种治疗多囊卵巢综合征无排卵症的中药制剂 |
CN105148119A (zh) * | 2015-10-02 | 2015-12-16 | 南京多宝生物科技有限公司 | 一种用于治疗多囊卵巢综合征的药物制剂 |
JPWO2013172304A1 (ja) * | 2012-05-16 | 2016-01-12 | 学校法人 関西大学 | エノキタケ抽出物の製造方法、エノキタケ抽出物および食品添加剤 |
CN115778932A (zh) * | 2023-02-02 | 2023-03-14 | 北京大学第三医院(北京大学第三临床医学院) | 一种低支链氨基酸饮食组合物在制备治疗多囊卵巢综合征的产品中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004300104A (ja) * | 2003-04-01 | 2004-10-28 | Nasu Bio Farm:Kk | 女性ホルモン不足症治療剤 |
-
2005
- 2005-02-04 CA CA2590549A patent/CA2590549C/en active Active
- 2005-02-04 WO PCT/JP2005/001697 patent/WO2006082649A1/ja not_active Application Discontinuation
- 2005-02-04 JP JP2006517881A patent/JP4464964B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004300104A (ja) * | 2003-04-01 | 2004-10-28 | Nasu Bio Farm:Kk | 女性ホルモン不足症治療剤 |
Non-Patent Citations (1)
Title |
---|
YUKIMURA H. ET AL.: "Wakan'yaku Chiryo o Kokoromita Tanohosei Ranso, Kasuitai Senshu ni yoru Funinsho Rei", SHINSHU ISHI, vol. 31, no. 3, 1983, pages 228 - 232, XP003000472 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168198B2 (en) | 2003-08-27 | 2012-05-01 | Kunihiko Tominaga | Therapeutic agent for polycystic ovary syndrome (PCOS) |
JPWO2013172304A1 (ja) * | 2012-05-16 | 2016-01-12 | 学校法人 関西大学 | エノキタケ抽出物の製造方法、エノキタケ抽出物および食品添加剤 |
CN104689070A (zh) * | 2015-02-26 | 2015-06-10 | 魏代淑 | 一种治疗多囊卵巢综合征无排卵症的中药制剂 |
CN105148119A (zh) * | 2015-10-02 | 2015-12-16 | 南京多宝生物科技有限公司 | 一种用于治疗多囊卵巢综合征的药物制剂 |
CN115778932A (zh) * | 2023-02-02 | 2023-03-14 | 北京大学第三医院(北京大学第三临床医学院) | 一种低支链氨基酸饮食组合物在制备治疗多囊卵巢综合征的产品中的用途 |
CN115778932B (zh) * | 2023-02-02 | 2023-11-21 | 北京大学第三医院(北京大学第三临床医学院) | 一种低支链氨基酸组合物在制备治疗多囊卵巢综合征的药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CA2590549C (en) | 2013-07-02 |
JP4464964B2 (ja) | 2010-05-19 |
JPWO2006082649A1 (ja) | 2008-10-23 |
CA2590549A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8168198B2 (en) | Therapeutic agent for polycystic ovary syndrome (PCOS) | |
DE60218299T2 (de) | Eine Dispersion aus Beta-Glukan enthaltenden hochfeinen Partikel, ein entsprechender Herstellungsprozess und die Verwendung der Dispersion | |
CN102415568B (zh) | 一种具有提高免疫力的保健品及其制备方法 | |
Namba | Maitake D-fraction: healing and preventive potential for cancer | |
US20060159698A1 (en) | Drug product for intestinal disease | |
EP1247529A1 (en) | Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs | |
US20060165720A1 (en) | Drug product for diabetes | |
WO2007126221A1 (en) | Composition comprising ursolic acid and oleanolic acid for improving and treating arthritis | |
JP4464964B2 (ja) | 多嚢胞性卵巣症候群(pcos)治療剤 | |
US6953580B2 (en) | Composition having physiological activity and production method thereof | |
CN111973620B (zh) | 用于预防和治疗激素依赖性皮炎的生物多糖及其应用 | |
US6726932B2 (en) | Fatty acid-containing composition | |
JPS6219525A (ja) | 植物起源の生物活性物質の製造法および同物質含有組成物 | |
US7214778B2 (en) | Glycoprotein with antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects from Grifola frondosa, and a method for preparing same | |
CN102379905B (zh) | 一种具有高效抗癌作用的含灵芝孢子油中药组合物 | |
CN1431015A (zh) | 一种抑制肿瘤的复合真菌药及制备方法 | |
JP4752233B2 (ja) | 免疫賦活剤 | |
JP2009024027A (ja) | 生理活性組成物 | |
CN105012268B (zh) | 牛樟芝提取物泡腾片 | |
KR100446061B1 (ko) | 유기용매흡착성 생약 미립구를 포함하는 숙취경감용 약학조성물 및 건강 보조식품 | |
CN104958274B (zh) | 一种牛樟芝泡腾片 | |
JPH0769913A (ja) | Aids症改善効果を有する物質の製造方法 | |
JPH01228917A (ja) | アラゲキクラゲ抽出物 | |
JPH0517208B2 (ja) | ||
CN110368476A (zh) | 一种治疗骨肉瘤的手术辅助药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006517881 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11573726 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2590549 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 11573726 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05709762 Country of ref document: EP Kind code of ref document: A1 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 5709762 Country of ref document: EP |